SKLB-197 exerts selectively inhibition against ataxia telangiectasia mutated and Rad3-related (ATR) kinase with IC50 of 0.013 μM, also displays potent antitumor activity against ATM-deficent tumors both in vitro and in vivo.
[1] Bin H, et al. Eur J Med Chem. 2022 Mar 15;232:114187.
















